Bangladesh Two-Step Registration: Recipe Approval and Final Registration

1. Key takeaways

For Bangladesh market authorisation of Class B/C/D medical devices, the Directorate General of Drug Administration (DGDA) applies a two-step approval process. The first step is Recipe Approval, also known as Primary Approval, which takes 3–4 months. Its function is narrow but decisive: it confirms whether the application contains all mandatory elements. Once this step is passed, DGDA issues a recipe approval letter and the application proceeds to the second step, Final Registration, which takes 30–40 days (a practical estimate of 2–3 months) and subjects the complete dossier to substantive review. Taken together, the two steps carry an official timeline of 4–6 months.

• The two-step process applies to marketing authorisation certificate applications for Class B, Class C and Class D devices only, and is drawn from registration practice (practical estimate).
• Step one, Recipe Approval, examines whether the application contains all mandatory elements; each application must go through a DGDA meeting; it takes approximately 3–4 months, and the output is a recipe approval letter.
• Step two, Final Registration, is a substantive review of all documents; it officially takes 30–40 days (a practical estimate of 2–3 months), and the output is the “Registration Certificate – Medical Device/IVD Import”.
• Class A devices are excluded from the two-step process and follow the declaration of conformity route, as set out in §4.5 of the DGDA Medical Device Registration Guidelines.
• The most common grounds for refusal are a missing CE certificate for Class B/C/D applications and a missing reference country CFS for Class C/D applications (practical estimate).

2. Legal basis

The table below consolidates the regulatory basis for the two-step process, distinguishing provisions taken from the DGDA Medical Device Registration Guidelines from points established through registration practice. Read together, the provisions show that the two-step architecture is anchored in the Guidelines for Class A exclusion, while the timing figures rest on a practical estimate.

3. Expert insights

Insight one: the first step does not assess whether the product works, but whether the dossier is complete. This is the most counter-intuitive feature of the two-step system. During Recipe Approval, DGDA does not evaluate the safety or effectiveness of the product; it checks the application against the list of mandatory elements. As a result, the overwhelming majority of step-one rejections are caused by missing documents, not by technical problems. This also means that the more completely the step-one preparation is done, the higher the pass rate becomes — in other words, step one is manageable. A manufacturer that treats the element list as a hard gate, and verifies each item before submission, can approach the first step with a high degree of confidence, whereas a manufacturer that treats it as a formality risks losing a full meeting cycle.

Insight two: the gap between the two steps is parallel-processing space, and it is the only lever that genuinely accelerates a Bangladesh project. Because step one examines only the completeness of the dossier, the manufacturer can prepare the materials required for step two while step one is still under review — the original CFS, the original empty boxes and labels, and the final registration fee. Running the two steps strictly in sequence wastes the single most valuable stretch of time in a 12–24 month cycle. Companies that treat the recipe approval letter as the trigger for starting step-two preparation effectively convert parallel time into serial time, and the cost is measured in additional months on the project calendar.

Insight three: the exclusion of Class A from the two-step process has a textual basis in the Guidelines. Section 4.5 requires only that Class A manufacturers inform DGDA through a declaration of conformity; no two-step process is established for that class. Chinese-language materials frequently present the “two steps” as a universal rule of Bangladesh registration, which is incorrect — Class A registration is completed in a single step and carries no government fee. Understanding this distinction prevents unnecessary budgeting and scheduling of Class A products through a process that was never designed for them, and it directs planning attention to where the two-step discipline actually matters, namely Class B, C and D.

4. Practical recommendations

• Run the Bangladesh project on a dual-track execution schedule: track one follows the step-one element checklist item by item, ticking each requirement as it is satisfied; track two advances the embassy attestation of the original CFS and the international logistics of the original packaging materials in parallel.
• Converge both tracks on the day the recipe approval letter is issued, so that the step-two submission can be filed without any additional waiting period.
• Conduct a refusal rehearsal before submission: self-check the dossier line by line against the return reasons DGDA applies most frequently — a missing CE certificate and a missing reference country CFS — so that refusal risk is eliminated before filing rather than discovered after the quarterly meeting has concluded.
• Treat the step-one element list as a hard gate and verify completeness before the dossier is bound, since step one assesses completeness rather than technical merit.
• Budget the fees for the two steps separately, with reference to the dedicated fee schedule for Bangladesh registration.
• Exclude Class A products from the two-step planning model and route them through the declaration of conformity instead.

5. Verification checklist

• □ It has been confirmed that the product is Class B/C/D and falls within the two-step process
• □ The step-one element checklist has been self-checked item by item (focus: CE certificate and reference country CFS)
• □ The step-one submission date has been back-scheduled against the quarterly committee meeting cycle
• □ The original documents required for step two have been prepared in parallel while step one is under review
• □ The fees for both steps have been budgeted separately (see the fee article)
• □ Class A products have been excluded from the two-step process and routed through the declaration of conformity

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of October 27, 2026.